Diabetes | Page 24 of 32 | SpiritIndia.com

Diabetes :: Updates on Counterfeit Blood Glucose Test Strips for LifeScan

On October 13, 2006, the U.S. Food and Drug Administration (FDA) alerted the public to counterfeit blood glucose test strips being sold in the United States for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors. These test strips are used by people with diabetes to measure their blood glucose. Today’s announcement provides two additional lot numbers that are included in the distribution of counterfeit products, along with descriptions of how to identify them.

Diabetes :: FTC and FDA Act Against Internet Vendors of Fraudulent Diabetes Cures

The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA), working with government agencies in Mexico and Canada, have launched a drive to stop deceptive Internet advertisements and sales of products misrepresented as cures or treatments for diabetes. The ongoing joint campaign has so far included approximately 180 warning letters and other advisories sent to online outlets in the three countries.

Diabetes :: Benefits of Actos – pioglitazone for type 2 diabetes unclear

According to a review of clinical trials, benefits of pioglitazone for type 2 diabetes is unclear. Marketed by Takeda Pharmaceuticals and Eli Lilly & Co. as Actos, pioglitazone belongs to a class of drugs called thiazolidinediones that work by increasing the body’s sensitivity to insulin, to better control patients’ blood sugar. It is used alone or in combination with other drugs if diabetes can’t be controlled by diet and exercise.

Diabetes :: Merck KGaA & Glenmark Pharmaceuticals Collaboration on DPPIV Inhibitor for Type 2 Diabetes

Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark?s DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the U.S. anti-trust agencies under the HSR Act.

Diabetes :: NovoMix insulin – effective & safe for patients with type 2 diabetes

Data presented at the European Association for the Study of Diabetes (EASD) 42nd Conference in Copenhagen showed NovoMix? 30 (biphasic insulin aspart) to have comparable efficacy to basal-bolus combination therapy, with a similar safety profile in patients previously treated with oral antidiabetic therapy. These findings follow on from the European Commission?s recent decision to approve NovoMix? 30 as the first premixed insulin suitable for once-daily initiation and subsequent intensification of treatment, if needed. The data also confirm the position of NovoMix? 30 as an appropriate treatment choice for patients who prefer a convenient, effective once or twice-daily insulin therapy.

Diabetes :: JANUVIA, sitagliptin phosphate – the First and Only DPP-4 Inhibitor for Type 2 Diabetes

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

Diabetes :: Top 5 Diabetes Diet Tips for Creating Healthy Meal Plan

Diet plays a key role in controlling your blood sugar. A healthy-eating plan tailored to your needs will do that and more. Majority of people affected with diabetes are overweight or obese. In fact, your risk of getting diabetes increases the more weight you put on.

Diabetes :: Novartis GALIANT study – clinical trials for diabetes drug Galvus – vildagliptin

Novartis announced the start of GALIANT, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus? (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).

Diabetes :: Alert on One Touch Basic/Profile and One Touch Ultra Blood Glucose Test Strips

The U.S. Food and Drug Administration (FDA) is alerting the public to counterfeit blood glucose test strips being sold in the United States for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors used by people with diabetes to measure their blood glucose.

Diabetes :: Plan Will Guide NIH Research in Type 1 Diabetes

The National Institutes of Health (NIH) has released a long range plan that will help to guide research in type 1 diabetes for the next decade. Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan identifies goals and objectives to exploit recent scientific advances in combating this autoimmune form of diabetes.